|
Acute Coronary Syndrome
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, the methylation of F2RL3 can affect the prognosis of different types of acute coronary syndrome and is closely related to mortality.
|
30574762 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of protease-activated receptor 4 in lung adenocarcinoma is associated with a more aggressive phenotype.
|
23886184 |
2013 |
|
Adenocarcinoma of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PAR-4 expression levels were analyzed in 4 established pancreatic tumor cell lines, 10 normal pancreatic tissues, 44 frozen tumor tissues and 25 paraffin-embedded pancreatic adenocarcinoma samples by Real Time RT-PCR, Western blot analysis and immunohistochemistry.
|
17893871 |
2008 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of both Dlk/ZIP kinase and its interaction partner Par-4 is maintained in four medulloblastoma cell lines investigated, whereas three of seven neuroblastoma cell lines have lost expression of Par-4.
|
11742505 |
2001 |
|
Alzheimer's Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Par-4 expression was enhanced, and mitochondrial dysfunction and apoptosis exacerbated, in cells expressing presenilin-1 mutations associated with early-onset inherited AD.
|
9701251 |
1998 |
|
Alzheimer's Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Par-4 down-regulation is often observed in cancer while up-regulation is characteristic of neurodegenerative conditions such as Alzheimer's disease.
|
30518159 |
2018 |
|
Alzheimer's Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Because the increased BACE1 activity observed in AD patients does not seem to arise from genetic mutations or polymorphisms in BACE1, the identification of PAR-4 as an endogenous regulator of BACE1 activity may have significant implications for developing novel therapeutic strategies for AD.
|
15671026 |
2005 |
|
Alzheimer's Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We now report that levels of Par-4, a protein recently linked to neuronal apoptosis in Alzheimer's disease, are increased in neurons in hippocampus of human patients with HIV encephalitis and in monkeys infected with a chimeric strain of HIV-1 and simian immunodeficiency virus.
|
10393834 |
1999 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Par-4 (prostate apoptosis response-4) is a leucine zipper protein that is pro-apoptotic and associated with neuronal degeneration in AD.
|
14627703 |
2004 |
|
androgen independent prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Par-4 selectively induces apoptosis in androgen-independent prostate cancer cells and Ras-transformed cells but not in androgen-dependent prostate cancer cells or normal cells.
|
12565819 |
2003 |
|
Atherothrombosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, they indicate that targeting PAR4 is an attractive antiplatelet strategy with the potential to treat patients at a high risk of atherothrombosis with superior safety compared with the current standard of care.
|
28053157 |
2017 |
|
Autoimmune Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Transcripts for genes (<i>F2RL3, EMILIN1</i> and <i>CDC42BPA</i>) previously identified as being differentially methylated or expressed in smoking or smoking-related cancers were overexpressed in smokers compared to non-smokers and the expression of transcripts for genes (<i>HERPUD1, GAB2, FAM167A</i> and <i>GLS</i>) previously associated with stress response, autoimmune disease and cancer were associated with telomere length.
|
29207374 |
2017 |
|
Autoimmune thrombocytopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
A reduction in response to GPVI and CLEC-2, but not protease-activated receptor 4 (PAR-4) peptide, was also observed in adult mouse platelets following immune thrombocytopenia, whereas receptor expression was not impaired.
|
29695020 |
2018 |
|
Bladder pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Repeated intravesical PAR4 (protease activated receptor 4) activation elicits persistent bladder pain lasting 5 days after the last treatment.
|
30708129 |
2019 |
|
Bladder pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We assessed involvement of the H<sub>2</sub>S pathway in protease-activated receptor 4 (PAR4)-induced bladder pain.
|
29357418 |
2018 |
|
Blood Coagulation Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, the strong signal emanating from PAR4 during platelet aggregation would provide an explanation for the mild bleeding diathesis of HPS.
|
12008957 |
2002 |
|
Breast cancer recurrent
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
These results identify Twist-induced epigenetic silencing of Par-4 as a targetable axis that promotes chemoresistance in recurrent breast cancer.
|
30148456 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, these results indicate that residual breast cancer tumor cell survival and recurrence requires circumventing Foxo-driven Par-4 upregulation and suggest that approaches to enforce Par-4 expression may prevent residual cell survival and recurrence.<i></i>.
|
29330285 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
PAR4 suppresses growth and invasiveness of breast cancer cells.
|
26977019 |
2016 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.
|
31217499 |
2019 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Relatively little is known about the role of Par-4 in breast cancer cell apoptosis.
|
23760770 |
2013 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We previously reported that downregulation of the proapoptotic protein Par-4 promotes tumor recurrence in genetically engineered mouse models of breast cancer recurrence.
|
30148456 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We also demonstrate in cell culture, in vivo, and in biochemical experiments that Akt regulation by Par-4 is mediated by PKCzeta, establishing a new paradigm for Akt regulation and, likely, for Ras-induced lung carcinogenesis, wherein Par-4 is a novel tumour suppressor.
|
18650932 |
2008 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These results establish the cooperation between Par-4 and PTEN as relevant for the development of prostate cancer and implicate the NF-kappaB pathway as a critical event in prostate tumorigenesis.
|
19470463 |
2009 |
|
Carcinogenesis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
The BALB/c strain (resistant allele) carried the Arg allele, whereas the SWR/J mouse strain (Par4-susceptible allele) carried the Cys variation, recently proven to functionally modulate tumorigenesis.
|
15592501 |
2005 |